FTC Says Hatch-Waxman Patent Infringement Suits Are Not Antitrust Proof

Drug Industry Daily
The Federal Trade Commission filed an amicus brief in the case of Takeda v. Zydus, urging the U.S. District Court of New Jersey to reject the notion that patent infringement suits brought under a law governing generic drugs are exempt from antitrust scrutiny.

To View This Article:


Subscribe To Drug Industry Daily